Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 81

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 81
---
 allows the drugs to stay in the bloodstream longer, reach their
target more precisely, and release their effects in a controlled way. We believe that this approach is designed to improve drug delivery
and treatment outcomes, subject to validation in clinical studies. At Revium Rx, we’re leveraging these features to target diseased
tissues, including tumors and infected areas, thereby minimizing effects on healthy cells.

We are developing a portfolio of lipid based
and Nano-Liposomal Particle NLP-based pharmaceutical candidates and plan to complete the development and commercialization of a series
of medical technologies comprised of:

| ● | A nanoparticle-based                                                                                                                                  
 formulation of mupirocin, a well-known and potent antibiotic currently limited to topical use due to its instability in blood when                    
 administered systemically. Our novel Nano-Mupirocin formulation, supported by both in vitro and in vivo animal studies, has demonstrated              
 promising potential for the treatment of severe, life-threatening infections caused by antibiotic-resistant bacteria, including Methicillin-Resistant 
 Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Neisseria gonorrhoeae.   If approved, the novel                             
 proprietary formulation of nano-mupirocin is intended to be administered systemically, providing extended presence in the bloodstream                 
 and enhanced delivery of mupirocin to inflamed areas of the body.                                                                                     |

| ● | A novel combination therapy designed                                                                                               
 to enhance the efficacy of existing cancer treatments: our novel nanoparticle-based formulation of angiotensin receptor blockers   
 (ARB), Nano-Candesartan, is being developed for intravenous administration, and is intended to improve treatment outcomes when     
 used in combination with established anticancer therapies.                                                                         |
| ● | Liposomal Protein-Loaded                                                                                                           
 Technology (LPLT), which is currently in early-stage development, represents a novel approach to immunization through innovative   
 nanoparticle-based vaccines. We are currently awaiting the completion by Prof. Barenholz of a SARS-CoV-2 challenge study involving 
 114 ACE2-transgenic mice to evaluate the short- and long-term benefits of the LPLT-based vaccination approach, which is expected   
 to resume in Q4 2025 and conclude in the first  quarter of 2026. We have an exclusive license to these liposomal based             
 vaccines and know-how, including potential applications other than SARS-CoV-2. The results of the study are necessary to establish 
 proof